The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD-1 inhibitor Jemperli (dostarlimab) – achieved a higher objective ...

The failure of Roche's tiragolumab in the SKYSCRAPER-01 trial in on-small cell lung cancer (NSCLC) has cast a pall over the TIGIT class ... GSK's PD-1 inhibitor Jemperli (dostarlimab), and ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

GSK (NYSE:GSK) announced Tuesday that the EU drug regulator has agreed to review depemokimab, an experimental monoclonal antibody targeting a class of cell signaling molecules called interleukin-5, ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

In Dungeons and Dragons, choosing one of the 14 DnD classes might be the most important decision you can make. D&D classes shape the way you play, allowing you to wield axes, cast spells, or even ...

GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer preve ...

Teva Pharmaceutical Industries Ltd. ADR 0.46% $24.53B ...

* Zero Cost Course Materials (ZCCM) Classes exclusively use digital course materials that are free of charge to students. These may have a low-cost option for print versions. A printable Schedule of ...